David G. Tubergen - Concepedia

Author

David G. Tubergen

University of Colorado Denver

Also Known As

D G Tubergen, D Tubergen, DAVID G. TUBERGEN, David G Tubergen, David G. Tubergen, David Tubergen, DavidG. Tubergen

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

University of Colorado Denver Children's Hospital Colorado University of Southern California The University of Texas MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center

About

David G. Tubergen is an author at University of Colorado Denver specializing in medicine, hematology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	468
2	Health Sciences	3	3	68
3	Cell Biology	3	3	155
4	Allergy	2	2	29
5	Blood Transplantation	1	1	21

David G. Tubergen

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
A syndrome of thrombosis and hemorrhage complicating l-asparaginase therapy for childhood acute lymphoblastic leukemia John R. Priest, Norma K.C. Ramsay, Peter G. Steinherz, The Journal of Pediatrics Pediatric HematologyL-asparaginase TherapyHematologyPediatrics	1982	180
Successful treatment of lymphohistiocytic reticulosis with phagocytosis with epipodophyllotoxin VP 16–213 Daniel R. Ambruso, Taru Hays, William J. Zwartjes, Cancer	1980	178
Splenectomy in the Management of the Thrombocytopenia of the Wiskott–Aldrich Syndrome Lawrence G. Lum, David G. Tubergen, Laurence Corash, New England Journal of Medicine ThrombopoiesisThrombosisBlood PlateletImmunodeficienciesHematology	1980	143
Phase I Trial and Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Topotecan Using a Five-Day Course in Children with Refractory Solid Tumors David G. Tubergen, Clinton F. Stewart, Charles B. Pratt, Journal of Pediatric Hematology/Oncology	1996	126
Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group. Fatih M. Uckun, Harland N. Sather, Paul S. Gaynon, PubMed	1997	113
Pharmacokinetics and Pharmacodynamics of Oral Methotrexate and Mercaptopurine in Children With Lower Risk Acute Lymphoblastic Leukemia: A Joint Children’s Cancer Group and Pediatric Oncology Branch Study Frank M. Balis, John S. Holcenberg, David G. Poplack, Blood	1998	112
PRODUCTION OF MACROPHAGE MIGRATION INHIBITION FACTOR BY CONTINUOUS CELL LINES David G. Tubergen, Joseph D. Feldman, E. M. Pollock, The Journal of Experimental Medicine ImmunologyImmunologic MechanismCell ProliferationCytoskeletonS Phase	1972	107
Young adults 16-21 years of age at diagnosis entered on childrens cancer group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatment James B. Nachman, Harland N. Sather, Jonathan D. Buckley, Cancer	1993	87
Ultrasonography for thyroid screening after head and neck irradiation in childhood cancer survivors Deborah B. Crom, Sue C. Kaste, David G. Tubergen, Medical and Pediatric Oncology	1997	76
The effect of methotrexate on the bioavailability of oral 6-mercaptopurine Frank M. Balis, John S. Holcenberg, Solomon Zimm, Clinical Pharmacology & Therapeutics	1987	76

Page 1